Article
Omer Ben‐Aharon, Racheli Magnezi, Moshe Leshno, and Daniel A. Goldstein
Season 1, Episode 12: The Future of Immuno-Oncology with Mark Frohlich
Michael Pietrack sits down with Mark Frohlich, a Harvard-trained medical Oncologist and CEO of Indapta Therapeutics! He discusses his experience in the Pharmaceutical industry as a pioneer in Immuno-Oncology. He emphasizes the importance of understanding the immune system and the integration of different approaches, including the role of artificial intelligence.
Regarding leadership, Frohlich highlights the importance of focusing on tasks that only the leader can do, giving honest feedback, and seeking out mentors for career development.
Key Points:
👨⚕️ Understanding the immune system is crucial in developing effective immunotherapies.
🔜The future of immunotherapy lies in integrating different approaches and leveraging artificial intelligence.
✋As a CEO, focus on tasks that only you can do and delegate other responsibilities.
🔰The "Kind Truth" help employees perform at their best.
📚Seek out mentors for guidance and career development.
Related Topics
You May Also Like
Omer Ben‐Aharon, Racheli Magnezi, Moshe Leshno, and Daniel A. Goldstein
Press Release
OVN Staff
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
Press Release
OVN Staff
Introducing OncologyVoiceNetwork.com
Article
A. Haslam, M.S. Kim, V. Prasad
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
Podcast
MSL Talk: Tom Caravela, Sarah Snyder
The Ideal Roadmap for New MSLs
Article
B. Gyawali, E. G. E. de Vries, U. Dafni, T. Amaral, J. Barriuso, J. Bogaerts, A. Calles, G. Curigliano, C. Gomez-Roca, B. Kiesewetter, S. Oosting, A. Passaro, G. Pentheroudakis, M. Piccart, F. Roitberg, J. Tabernero, N. Tarazona, D. Trapani, R. Wester, G.